New Zealand markets closed

BIIB Jan 2025 110.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.25000.0000 (0.00%)
As of 10:58AM EDT. Market open.
Full screen
Previous close1.2500
Expiry date2025-01-17
Day's range1.2500 - 1.2500
Contract rangeN/A
Open interestN/A
  • GlobeNewswire

    FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

    TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.

  • Motley Fool

    Is Biogen Stock a Buy Now?

    It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.

  • Zacks

    Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs

    Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.